Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
A Trial to Determine if Quabodepistat is Processed Differently in Adults with Reduced Liver Function Compared to Adults with Normal Liver Function
Otsuka Beijing Research Institute
Tuberculosis
1 trial -
A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults
Otsuka Beijing Research Institute
Incomplete Response - Major Depressive Disorder (IR-MDD)
1 trial -
A phase 1 trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with autoimmune disease(s)
Otsuka Beijing Research Institute
Systemic lupus erythematosus, Immune-mediated focal segmental glomerulosclerosis, Alopecia Areata
1 trial -
A positron emission tomography study of synaptic nerve cells proteins alpha-7 nicotinic acetylcholine receptors in brain of healthy volunteers and patients with mild cognitive impairment and Alzheimer´s disease.
The George Institute
Alzheimer´s disease
1 trial -
A randomised, assessor-blinded, controlled, healthy volunteer, Phase I study to assess skin irritation and sensitization potential of a novel 5% lidocaine medicated plaster
The George Institute
None. Healthy subjects
1 trial -
A study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and pertuzumab in adult patients with refractory metastatic Her2 positive breast cancer
The George Institute
Refractory metastatic Her2 positive breast cancer
1 trial -
A study to assess the safety and tolerability of next-generation neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) therapy. NEXTGEN-TIL-ACT
The George Institute
Advanced epithelial tumors and immune checkpoint blockade (ICB) resistant solid tumors
1 trial -
A study to find out how healthy people tolerate a new drug called S221237.
The George Institute
Parkinson disease (PD)
1 trial -
An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)
The George Institute
Neoadjuvant therapy in locally-advanced rectal cancer
1 trial -
Autologous tolerogenic dendritic cells (ATDC) for highly sensitized kidney transplant recipients
The George Institute
Kidney trasplants
1 trial -
Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fasting Conditions.
The George Institute
No medical condition.
1 trial -
Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fed Conditions.
The George Institute
No medical condition.
1 trial -
Bioequivalence of One Tablet of Gliclazide MR 90 mg (S005190) and One and a Half Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fed Conditions.
The George Institute
No medical condition.
1 trial -
CAR123 T cell treatment of relapsed/refractory hematologic malignancies.
The George Institute
Relapsed/refractory CD123+ hematological malignancies: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Lymphoblastic Leukemia.
1 trial -
CART19 cells effects in patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.
The George Institute
Relapsed/refractory CD19+ Acute Lymphoblastic Leukaemia and Non-Hodgkin Lymphoma
1 trial -
CD5CAR-NK cells for refractory invasive mold disease
The George Institute
refractory invasive mold disease
1 trial -
CLADRIBINE DOSE ESCALATION IN CONDITIONING REGIMEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (Allo-HSCT) FOR REFRACTORY ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
The George Institute
Acute leukemia and myelodysplastic syndromes
1 trial -
CLEVER PEPTIDE : Open-label, non-controlled, multicenter, dose escalation, first-in-human clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel or with gemcitabine in patients with recurrent and/or metastatic solid cancer
The George Institute
Patients with recurrent and/or metastatic solid cancer.
1 trial -
Comparative Pharmacokinetic of S221237 Tablets in Healthy Participants Under Fed Conditions
The George Institute
No medical condition
1 trial -
Exploratory Bioavailability of Three Formulations of Gliclazide MR Tablets 120 mg (I.R.I.S.) in Healthy Volunteers Under Fed Conditions (High Fat High Calorie Meal and Standard Meal).
The George Institute
No medical condicion.
1 trial -
First in human pilot study to assess the safety and efficacy of dendritic cells loaded with frameshift derived neopeptides for the prevention of cancer in Lynch Syndrome carriers
The George Institute
Lynch Syndrome
1 trial -
First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma
The George Institute
Relapsed/refractory B-cell aggressive lymphoma
1 trial -
M1774 (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients with advanced solid tumors
The George Institute
Patients with pretreated, metastatic or locally advanced cancer for the dose escalation part and dose expansion cohorts in patients with advanced triple-negative breast cancers and advanced cancers with ATM mutation.
1 trial -
Multiple-Dose Study in Healthy Participants Under Fasting Conditions to Evaluate the Bioequivalence of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide SR 1.5 mg and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg.
The George Institute
No medical condition.
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources